Amsterdam, the Netherlands, and Holzgerlingen, Germany, October 30, 2019, 10:00 am CET - Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that the Curetis Group Companies will be attending several key conferences in the fourth quarter of 2019.
November 2019
EIT Health German-French Bilateral Meeting, November 4-5 2019 – Mannheim, Germany (Ares Genetics GmbH)
54th Annual Northeast Branch American Society for Microbiology, November 7-8, 2019 – Randolph, MA, USA (Curetis USA Inc.)
DICON/DASON Fall 2019 Symposium (Duke Infection Control Outreach Network / Duke Antimicrobial Stewardship Outreach Network), November 8, 2019 – Raleigh, NC, USA (Curetis USA Inc.)
Southeastern Association of Clinical Microbiology (SEACM) Annual Fall Meeting, November 14-16, 2019 – Myrtle Beach, SC, USA (Curetis USA Inc.)
DxPx - Diagnostics and Research Tools Partnering Conference, November 18, 2019 – Düsseldorf, Germany (Ares Genetics & Curetis GmbH)
European Summit of Industrial Biotechnology, November 18-20, 2019 – Graz, Austria (Ares Genetics GmbH)
Emerging Antimicrobials and Diagnostics in AMR 2019, November 19-20, 2019 – Amsterdam, The Netherlands (Ares Genetics GmbH & Curetis GmbH)
EPAASM 49th Annual Symposium (Eastern Pennsylvania Branch of the American Society for Microbiology), November 22, 2019 – Philadelphia, PA, USA (Curetis USA Inc.)
December 2019
3rd Congress Immunotherapies & Innovations for Infectious Diseases, December 3-4, 2019 – Lyon, France (Ares Genetics GmbH)
ASPH Midyear Clinical Meeting (American Society of Health-System Pharmacists), December 8-12, 2019 – Las Vegas, NV, USA – (Curetis USA Inc., booth #773)
13. Nationaler Qualitätskongress Gesundheit, December 12-13, 2019 – Berlin, Germany (Ares Genetics GmbH)
###
About Curetis
Curetis N.V.’s (Euronext: CURE) goal is to become a leading provider of innovative solutions for molecular microbiology diagnostics designed to address the global challenge of detecting severe infectious diseases and identifying antibiotic resistances in hospitalized patients.
Curetis’ Unyvero System is a versatile, fast and highly automated molecular diagnostic platform for easy-to-use, cartridge-based solutions for the comprehensive and rapid detection of pathogens and antimicrobial resistance markers in a range of severe infectious disease indications. Results are available within hours, a process that can take days or even weeks if performed with standard diagnostic procedures, thereby facilitating improved patient outcomes, stringent antibiotic stewardship and health-economic benefits. Unyvero in vitro diagnostic (IVD) products are marketed in Europe, the Middle East, Asia and the U.S.
Curetis’ wholly owned subsidiary Ares Genetics GmbH offers next-generation solutions for infectious disease diagnostics and therapeutics. The ARES Technology Platform combines what the Company believes to be the most comprehensive database worldwide on the genetics of antimicrobial resistances, ARESdb, with advanced bioinformatics and artificial intelligence.
For further information, please visit www.curetis.com and www.ares-genetics.com.
Legal Disclaimer
This document constitutes neither an offer to buy nor an offer to subscribe for securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.
The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.
This press release includes statements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “intends,” “targets,” “may,” “will,” or “should” and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis’ actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
Contact details
Curetis’ Contact Details
Curetis N.V.
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr@curetis.com or ir@curetis.com
www.curetis.com - www.unyvero.com
International Media & Investor Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
Attachment
